Autres langues Bristol-Myers Squibb Company Lima

Actions

BMYUS

US1101221083

Produits pharmaceutiques

Cours en clôture Lima 28/09/2026			Varia. 5j.	Varia. 1 janv.
62,62 ^USD	0,00%		0,00%	+16,26%

29/09	Le secteur pharmaceutique mise davantage sur l’IA pour réduire les coûts et les délais	RE
29/09	Summit obtient un investissement de 2 milliards de dollars d’AstraZeneca et une collaboration sur des essais de médicaments contre le cancer	MT

Autres langues

29/09	Pharma sector doubles down on AI to slash costs, timelines
29/09	Summit Secures $2 Billion AstraZeneca Investment, Cancer Drug Trial Collaboration
29/09	Summit soars after $2 billion investment from AstraZeneca for cancer therapies
29/09	Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
28/09	US drugmakers turn to China for licensing deals
25/09	Bristol Myers Squibb Announces First Presentation Of Results For ZENBEXUS In Combination With Daratumumab From Phase 3 EXCALIBER-RRMM Trial In Relapsed Or Refractory Multiple Myeloma
25/09	Bristol-Myers Squibb Says Zenbexus Combination Doubles MRD-Negative Complete Response in Multiple Myeloma Trial
25/09	Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
22/09	Onco360(R) is a participating specialty pharmacy in the ZENBEXUS (iberdomide) limited dispense network
21/09	Onco360 Oncology Pharmacy Is Selected As Participating Specialty Pharmacy In ZENBEXUS Limited Dispense Network By Bristol-Myers Squibb
21/09	Pharma sector doubles down on AI to slash costs, timelines
21/09	Two favorable EU opinions for AstraZeneca
18/09	Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
18/09	Anthropic quietly sets up biology lab as it ramps AI drug program
18/09	US weighs allowing most pharma licensing deals with China, sources say
17/09	Bristol Myers Squibb Presents Sotyktu (Deucravacitinib) Data Showing Durable Efficacy And Consistent Safety In Adults With Psoriatic Arthritis Over Two Years
17/09	Bristol Myers Squibb Reports Sustained Sotyktu Responses in Psoriatic Arthritis Through 2 Years
17/09	Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
17/09	Drugmakers prepare for next phase of space pharmaceuticals as ISS retirement nears
16/09	Novo Nordisk to Collaborate With Anthropic to Help Accelerate Drug Discovery, Development
16/09	Analystenempfehlungen: BMW, Elmos Semiconductor, Schindler, Stellantis, Apple, Chipotle…
16/09	Pharma sector doubles down on AI to slash costs, timelines
16/09	Wall Street vor der Zinsabrechnung
16/09	Afternoon Meeting: La hora de la verdad de los tipos de interés
16/09	Wall Street's Rate Reckoning